An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease
| Autor: | Ana W. Capuano, Jerry R. Colca, Dawn C. Matthews, Raj C. Shah, Randolph D. Andrews, James T. VanderLugt, Debra A. Fleischman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
mTOT modulator
Male medicine.medical_specialty Pyridines medicine.medical_treatment Carbohydrate metabolism Placebo Brain mapping Article Insulin resistance Double-Blind Method Alzheimer Disease Fluorodeoxyglucose F18 Internal medicine insulin resistance medicine Humans FDG-PET insulin sensitizer Aged Brain Mapping Insulin Brain medicine.disease Pons 3. Good health Endocrinology Glucose Treatment Outcome Neurology Posterior cingulate Positron-Emission Tomography Female Thiazolidinediones Neurology (clinical) Alzheimer's disease Radiopharmaceuticals Psychology Mental Status Schedule Alzheimer’s disease Central Nervous System Agents |
| Zdroj: | Current Alzheimer Research |
| ISSN: | 1875-5828 1567-2050 |
| Popis: | Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|